The clinical and diagnostic implications mosaicism in the neurofibromatoses

10.1001/jama.1997.03550010065042

Friedman JM Gutmann DH MacCollin M Riccardi VM eds. Neurofibromatosis: phenotype natural history and pathogenesis. 3rd ed. Baltimore: Johns Hopkins University Press; 1999.

Viskochil DH. Gene structure and expression. In: Upadhyaya M Cooper DN eds. Neurofibromatosis type 1 from genotype to phenotype. Oxford: Bios Scientific Publishers; 1998: 39–53.

MacCollin M Gusella JF. Neurofibromatosis 2. Molecular biology. In: Friedman JM Gutmann DH MacCollin M Riccardi VM eds. Neurofibromatosis: phenotype natural history and pathogenesis. 3rd ed. Baltimore: Johns Hopkins University Press; 1999:357–362.

Huson SM. Neurofibromatosis 1: a clinical and genetic overview. In: Huson SM Hughes RAC eds. The neurofibromatoses: pathogenetic and clinical overview. London: Chapman & Hall; 1994: 160–203.

10.1093/brain/111.6.1355

10.1136/jmg.35.8.624

Evans DGR, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med . 1992; 84: 603–618.

Huson SM, Ruggieri M. The various presentations of neurofibromatosis type 2 (NF2) in childhood. J Med Genet . 2000; 36 (suppl 1): 289.Abstract.

10.1016/S1071-9091(98)80003-X

10.1212/WNL.43.10.2096

10.1212/WNL.46.4.1072

Evans DGR, Mason S, Huson SM, Ponder M, Harding AE, Strachan T. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Med Genet . 1997; 62: 361–366.

10.1086/301633

10.1212/WNL.54.1.71

Hall JG. Review and hypotheses: somatic mosaicism: observations related to clinical genetics. Am J Hum Genet . 1988; 43: 355–363.

Happle R. Principles of genetics mosaicism and molecular biology. In: Harper J Oranje JM Rose M eds. Textbook of pediatric dermatology. Vol. 2. Oxford: Blackwell Science; 2000:1037–1056.

10.1007/s004390050708

Jonkman MF. Revertant mosaicism in human genetic disorders. Am J Med Genet 199;85:361–364.

10.1001/archderm.1993.01680320094012

10.1002/(SICI)1096-8628(19990806)85:4<351::AID-AJMG8>3.0.CO;2-0

International Symposium on Mosaicism in Human Skin in honour of Rudolf Happle. Am J Med Genet 1999;85:323–364.

Happle R. Pigmentary patterns associated with human mosaicism: a proposed classification. Eur J Dermatol . 1993; 3: 170–174.

10.1002/(SICI)1096-8628(19990806)85:4<338::AID-AJMG5>3.0.CO;2-8

10.1086/302412

10.1056/NEJM199411243312102

10.1038/343558a0

10.1002/ajmg.1320460217

Tonsgard JH, Yelavarthi KK, Cushner S, et al. Do NF1 gene deletions result in a characteristic phenotype? Am J Med Genet . 1997; 28: 80–86.

Wu Bai-Lin Boles RG Weremowicz HYS et al. Somatic mosaicism for deletion of the entire NF1 gene identified by FISH. Hum Genet 1996;99:209–213.

10.1086/302709

Colman SD, Rasmussen SA, Ho VT, et al. Somatic mosaicism in a patient with neurofibromatosis type 1. Am J Hum Genet . 1996; 58: 484–490.

10.1002/(SICI)1098-1004(1997)9:5<452::AID-HUMU12>3.0.CO;2-1

10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N

10.1136/jmg.27.5.307

Evans DG, Wallace AJ, Wu CL, et al. Somatic mosaicism: a common cause of classic disease in tumour-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet . 1998; 63: 727–736.

10.1001/archderm.1931.01450010722022

Crowe FW Schull WJ Neel JV. A clinical pathological and genetic study of multiple neurofibromatosis. Springfield: Charles C. Thomas; 1956.

10.1001/archderm.1977.01640060133020

Riccardi VM. Neurofibromatosis: clinical heterogeneity. Curr Probl Cancer . 1982; 7: 1–34.

10.1001/archderm.1987.01660310085020

Viskochil D Carey JC. Alternate and related forms of the neurofibromatoses. In: Huson SM Hughes RAC eds. The neurofibromatoses: pathogenetic and clinical overview. London: Chapman & Hall; 1994: 445–474.

MacCollin M. Neurofibromatosis 2. Clinical aspects. In: Friedman JM Gutmann DH MacCollin M Riccardi VM eds. Neurofibromatosis: phenotype natural history and pathogenesis. 3rd ed. Baltimore: Johns Hopkins University Press; 1999:299–326.

Huson SM Ruggieri M. The neurofibromatoses. In: Harper J Oranje JM Rose M eds. Textbook of pediatric dermatology. Vol. 2. Oxford: Blackwell Science; 2000:1204–1224.

10.1001/archderm.1995.01690240131031

10.1001/archderm.1995.01690200099023

10.1001/archderm.1997.03890480025004

Sybert VP. Genetics of skin disorders. New York: Oxford University Press; 1997.

10.3171/jns.2000.92.2.0342

Hix K, Rothner D, Cohen B. Segmental neurofibromatosis: analysis of 14 cases. Ann Neurol . 1998; 44: 575–576. Abstract.

10.1038/sj.ejhg.5200493

10.1111/j.1365-2133.1994.tb06893.x

Rubenstein A, Bader JL, Aron AA, Wallace S. Familial transmission of segmental neurofibromatosis. Neurology . 1983; 33 (suppl 2): 76.Abstract.

Segal R. Segmental neurofibromatosis of the sciatic nerve: case report. Neurosurgery . 1993; 33: 948.

10.1101/gad.5.3.331

Gardner RL. Cell lineage and cell commitment in the early mammalian embryo. In: Warshaw JB ed. The biological basis of reproductive and developmental medicine. Amsterdam: Elsevier; 1983: 31–41.

Bourn D, Carter SA, Evans D, et al. A mutation in the neurofibromatosis type 2 tumour-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet . 1993; 55: 69–73.

10.1136/jmg.34.11.934

10.1093/hmg/7.13.2095

MacCollin M, Jacoby LB, Jones D, et al. Somatic mosaicism of the neurofibromatosis type 2 suppressor-gene. Neurology . 1997; 48: A429.Abstract.

10.1002/ajmg.1320520411